Home » Topics » Substance use and poisoning, BioWorld Science

Substance use and poisoning, BioWorld Science
RSS

Patient enrollment advances ahead of schedule in phase III Probuphine trial

Aug. 4, 2010

No Comments

FDA grants CBLB-502 fast track status for acute radiation syndrome

July 23, 2010

No Comments

Cangene's option to license Maxygen's MAXY-G34 for ARS expires

July 19, 2010

No Comments

Nabi completes enrollment in first of two phase III NicVAX trials

July 15, 2010

No Comments

Effect of citalopram on drinking depends on goals of alcohol-dependent subjects

July 13, 2010

No Comments

FDA schedules review of Alkermes' Vivitrol sNDA for opioid dependence

June 21, 2010

No Comments

Protalix BioTherapeutics completes phase I trial of PRX-105

June 10, 2010

No Comments

FDA grants priority review to Vivitrol sNDA for opioid dependence

May 27, 2010

No Comments

Cleveland BioLabs completes dosing in second safety study for CBLB-502

May 11, 2010

No Comments

BARDA exercises options on Cleveland BioLabs contract to develop CBLB-502

May 3, 2010

No Comments

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Substance use and poisoning, BioWorld Science
RSS

Patient enrollment advances ahead of schedule in phase III Probuphine trial

FDA grants CBLB-502 fast track status for acute radiation syndrome

Cangene's option to license Maxygen's MAXY-G34 for ARS expires

Nabi completes enrollment in first of two phase III NicVAX trials

Effect of citalopram on drinking depends on goals of alcohol-dependent subjects

FDA schedules review of Alkermes' Vivitrol sNDA for opioid dependence

Protalix BioTherapeutics completes phase I trial of PRX-105

FDA grants priority review to Vivitrol sNDA for opioid dependence

Cleveland BioLabs completes dosing in second safety study for CBLB-502

BARDA exercises options on Cleveland BioLabs contract to develop CBLB-502

Today's news in brief

Today's news in brief

Type 1 diabetes breakthrough? Sana threads key ‘islet,’ SC-451 to advance

Australia’s Celosia heads toward clinic with gene therapy for ALS

Sangamo stock plunges as Pfizer leaves hemophilia partnership

Substance use and poisoning, BioWorld Science RSS

Substance use and poisoning, BioWorld Science
RSS